AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$CBIO

Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Crescent Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights Completed dose escalation in Phase 1/2 ASCEND trial of CR-001 with more than 125 patients dosed across United States, Europe and South Korea; enrolling standard of care chemotherapy com

Event · Earnings
Original reporting
SEC EDGAR 8-K
Published Nov 12, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CBIO
Neutral
high confidence
Mentioned
$CBIO
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CBIONeutralMed
01

Why it matters

The filing provides the first public disclosure of Q3 financials and key trial milestones, setting expectations for data releases in 2027.

02

Market read

New earnings and clinical data create a short‑term trading catalyst for CBIO, with potential spill‑over to similar oncology biotech stocks.

03

What to watch

The partnership with Kelun‑Biotech in China could expose the company to regulatory risk and execution challenges.

Relevance 7/10Novelty 8/10Timing: today

Background

Crescent Biopharma is a clinical‑stage biotech developing PD‑1×VEGF bispecific antibodies and ADCs for oncology.

Company-level read

Ticker impact

$CBIONeutralHigh confidence
Context

Crescent Biopharma filed its Q3 2026 earnings and disclosed completion of dose escalation in the ASCEND trial and first patient dosing in the APOLLO trial.

Expected impact

likely pressure as the market anticipates data readouts in 2027, with potential upside if early results are positive

Evidence & confidence

Quarterly earnings provide fresh cash‑flow visibility, while trial progress is material for a biotech; both are new primary disclosures.

Market effects

Sector

Positive trial progress may lift peer biotech stocks focused on ADC and bispecific platforms.

Regional

Limited to US and Nasdaq‑listed biotech investors.

Global

Modest; the news is company‑specific without broader macro impact.

Counterpoint

What could challenge this read

If the upcoming data disappoints, the stock could face a sharp sell‑off despite the cash runway.

Key entities

  • company
    Crescent Biopharma, Inc.

    Nasdaq‑listed biotech reporting Q3 results and trial updates.

  • partner
    Kelun‑Biotech

    Chinese partner collaborating on CR‑001 and CR‑003 development.

Read at source← All news

Related articles

$CBIOMed

H.C. Wainwright reiterates Crescent Biopharma stock rating at buy

H.C. Wainwright reiterated a Buy rating and $36.00 price target on Crescent Biopharma (CBIO), citing progress in mid-stage clinical trials for its CR-001 drug. The stock trades at $11.84, with potential upside of over 200%. Crescent announced completion of dose escalation in its ASCEND trial and enrollment of over 125 patients. The company aims to dose over 2,000 patients by mid-2027 and start Phase 3 trials in early 2028.

investing.com
$CBIOHighAI 8/10

Stifel reiterates Crescent Biopharma stock rating on pipeline progress

Stifel maintained a Buy rating and $28.00 price target for Crescent Biopharma (CBIO) after its pipeline update, noting progress in trials and patient dosing. The stock, trading at $12.48, has dropped 16% in a week. Crescent recently raised $143.7M via a public offering, with H.C. Wainwright upgrading its rating to Buy with a $36.00 target. The company's enterprise value is below $500M, and it expects to dose over 2,000 patients by mid-2027.

investing.com
$CBIOMed

Crescent Biopharma advances CR-001 combos, clears IND for CR-002 and sets mid‑2027 data timelines

Crescent Biopharma (CBIO) announced enrollment in CR-001 chemo combination cohorts and IND allowance for CR-002, with initial data expected in 2027. The company completed CR-001 monotherapy dose escalation and expects initial monotherapy data from over 125 patients and ORR in up to 12 1L NSCLC patients by Q1 2027. The FDA allowed IND for CR-002, with a global Phase 1/2 APOLLO trial to start Q4 2026 and initial data anticipated in H2 2027.

tradingview.com
$CBIOMed

Crescent Biopharma, Inc. issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x…

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 15, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care

SEC EDGAR 8-K
$CBIOHigh

Crescent Biopharma stock rating upgraded to buy at H.C. Wainwright

H.C. Wainwright upgraded Crescent Biopharma (CBIO) to Buy with a $36.00 price target, citing potential catalysts in 2027. The stock is currently trading at $13.94. The firm highlighted the company's antibody-drug conjugate pipeline and recent public offering raising $143.7 million. CBIO's balance sheet shows more cash than debt, a strength for a clinical-stage biotech.

investing.com